SCHEDULE: BlackRock Boosts Stake in Veracyte to 15.2%

BlackRock, Inc. has filed an amended Schedule 13G, disclosing a 15.2% beneficial ownership stake in Veracyte, Inc.'s common stock as of July 31, 2025.

Summary

• BlackRock, Inc. reported beneficial ownership of 11,930,018 shares of Veracyte, Inc. common stock.
• This aggregate amount represents 15.2% of Veracyte, Inc.'s outstanding common stock.
• BlackRock holds sole voting power over 11,712,378 shares and sole dispositive power over 11,930,018 shares.
• The filing is an Amendment No. 16 to a Schedule 13G, indicating a change in previously reported ownership.
• The securities are held in the ordinary course of business and not for the purpose of changing or influencing control of Veracyte, Inc.
• iShares Core S&P Small-Cap ETF, a subsidiary of BlackRock, holds more than 5% of Veracyte's common stock.

Sentiment

Score: 5

Explanation: The filing is a factual disclosure of beneficial ownership, which is neutral in sentiment. While a large institutional stake can be seen positively, the filing itself does not convey explicit positive or negative news about the company's operations or financial performance.

Positives

• BlackRock's significant 15.2% stake indicates strong institutional conviction in Veracyte, Inc., potentially signaling stability and long-term interest.
• The filing explicitly states that the securities are held in the ordinary course of business and not for the purpose of changing or influencing control, which can reassure existing management and investors.

Negatives

• No explicit negatives are presented in this beneficial ownership disclosure filing.

Risks

• The filing itself does not detail specific operational or financial risks for Veracyte, Inc.; it is a disclosure of beneficial ownership.

Future Outlook

This filing is a disclosure of beneficial ownership and does not contain forward-looking statements or guidance regarding Veracyte, Inc.'s future performance or strategic outlook.

Management Comments

• "To the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under 240.14a-11."

Industry Context

A significant increase or maintenance of a large institutional stake by a major asset manager like BlackRock can be viewed by the market as a vote of confidence in the company's long-term prospects. Such holdings are common for publicly traded companies, especially those included in indices tracked by large ETFs, like the iShares Core S&P Small-Cap ETF mentioned.

Comparison to Industry Standards

• This filing is a disclosure of beneficial ownership and does not contain performance metrics or operational results that can be directly compared to industry standards or specific comparable companies/projects.

Stakeholder Impact

• Shareholders: The disclosure of a significant institutional holding by BlackRock may provide a sense of stability and institutional backing for Veracyte, Inc.'s stock.

Key Dates

Keywords

BlackRock, Veracyte, Schedule 13G, Beneficial Ownership, Institutional Investor, Common Stock, Investment Management, Asset Management